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Prader–Willi	 syndrome	 (PWS)	 is	 a	 complex	neurodevelopmental	 genetic	 condition	that	was	first	described	in	1956	by	Prader	
and	colleagues.	The	condition	is	characterized	by	
a	 recognizable	 pattern	 of	 dysmorphic	 features	
as	 well	 as	 major	 neurological,	 developmental,	
behavioural	and	psychiatric	differences	(Cassidy	
and	 Driscoll,	 2009;	 Butler,	 2011;	 McAllister	
et	 al,	 2011;	 McCandless	 and	 The	 Committee	
on	 Genetics,	 2011;	 Prader–Willi	 Syndrome	
Association	UK	(PWSA(UK)),	2012).	 It	has	been	
highlighted	 that	 PWS	 should	 be	 referred	 to	
as	 a	 genomic	 condition	 rather	 than	 a	 genetic	
condition	 because	 of	 its	 genomic	 imprinting	
feature	(Cassidy	and	Driscoll,	2009;	McCandless	
and	The	Committee	on	Genetics,	2011).	
The genotype of PWS
Each	cell	in	the	human	body	contains	genetic	material	
inside	its	nucleus	in	the	form	of	chromosomes	(the	
genotype);	 23	 pairs	 of	 chromosomes	 composed	
of	two	strands	of	deoxyribonucleic	acid	(DNA)	are	
linked	together	to	form	a	‘double	helix’,	with	one	
chromosome	from	each	pair	being	inherited	from	
each	 parent.	 The	 DNA	 genes	 (segments	 of	 the	
DNA)	provide	the	genetic	code	for	specific	amino	
acids,	which	in	turn	form	specific	proteins	—	the	
building	blocks	of	the	human	body.	Any	disruption	
or	 changes	 to	 DNA	 may	 result	 in	 alterations	 to	
protein	expression	and	function	(the	phenotype).	
Normally	 the	 two	copies	of	genes	 (one	 from	
each	 parent)	 are	 equally	 controlled,	 but	 for	 a	
small	proportion	of	genes	certain	sections	of	the	
genome	are	only	activated	if	they	are	 inherited	
from	a	parent	of	a	particular	sex.	Therefore,	for	
some	areas	of	the	genetic	material	the	maternally	
and	 paternally	 derived	 copies	 are	 controlled	
differently.	 The	 term	 ‘imprinting’	 is	 used	 to	
describe	the	epigenetic	mechanism	causing	this	
unequal	control	of	paternal	and	maternal	genes.	
A	small	number	of	genes	are	subject	to	genomic	
imprinting,	 where	 a	 gene	 from	 a	 parent	 of	 a	
particular	sex	is	‘switched	off’	—	silenced	or	not	
active	as	a	result	of	being	imprinted.
Imprinted	genes	tend	to	be	organized	in	clusters	
regulated	by	one	or	more	imprinting	centres	(ICs).	
In	 the	 case	 of	 PWS,	 the	 genes	 on	 chromosome	
15q11.2–13	 are	 subject	 to	 this	 epigenetic	
modification,	and	it	is	only	the	copy/gene	inherited	
from	 the	 father	 that	 is	 normally	 expressed;	 the	
maternal	copy	is	quite	normally	‘imprinted’	and	not	
active.	 Under	 normal	 circumstances,	 just	 having	
this	one	active	copy	from	the	father	is	sufficient	for	
normal	function;	however,	PWS	develops	when	a	
person	has	a	deletion	or	mutation	at	15q11.2–13	
on	the	paternal	copy	and	the	only	active	copy	of	the	
relevant	genes	are	deleted	or	lost	(Goldstone,	2004;	
Cassidy	and	Driscoll,	2009;	Butler,	2011;	McAllister	
et	 al,	 2011;	McCandless	 and	The	Committee	on	
Genetics,	2011;	PWSA(UK),	2012)	(Figure 1).	
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Dykens	 et	 al	 (2011)	 highlight	 that	 the	
conditions	PWS	and	Angelman	syndrome	(AS),	a	
condition	caused	by	disruption	in	the	maternally	
expressed	ubiquitin-protein	 ligase	E3A	 (UBE3A)	
gene	in	the	same	q11–13	region	of	chromosome	
15,	made	molecular	genetic	history	as	 the	first	
disorders	 to	 show	 these	 effects	 of	 parent-of-
origin	genomic	imprinting.	
Cause of PWS
PWS	is	a	complex	genomic	imprinted	condition	
resulting	 from	 the	 absence	 of	 normally	
active	 paternally	 expressed	 genes	 from	 the	
chromosome	15q11.2–13	region,	with	a	number	
of	underlying	causative	factors.	Deletions	in	the	
paternally	 inherited	 chromosome	 15q11.2–13	
region	account	 for	70–75%	of	cases;	25–30%	
from	maternal	uniparental	disomy	 (mUPD)	and	
the	remaining	from	mutations	or	defects	of	the	
IC	 (Cassidy	 and	 Driscoll,	 2009;	 Butler,	 2011;	
DuBose	 et	 al,	 2011;	 McAllister	 et	 al,	 2011;	
McCandless	 and	 The	 Committee	 on	 Genetics,	
2011).	
There	 are	 three	 main	 subtypes	 of	 PWS	
(Table 1),	 with	 the	 common	 feature	 being	
loss	 of	 expression	 of	 the	 paternally-expressed	
imprinting	genes	in	the	critical	region.	
Deletions
Deletions	are	classified	according	to	size:	larger	
type	 I	 deletions	 (BP1–BP3);	 and	 smaller	 type	
II	 deletions	 (BP2–BP3).	 There	 are	 two	 major	
proximal	 chromosome	 breakpoints	 (BP1	 and	
BP2)	and	a	distal	breakpoint	(BP3)	in	the	15q11–
13	region	(Figure 2).
mUPD	
mUPD	occurs	when	both	copies	of	chromosome	
15	 are	 maternally	 inherited	 and	 the	 father’s	
chromosome	15	is	absent	(instead	of	inheriting	
one	 from	 each	 parent).	 Therefore,	 neither	
copy	 of	 the	 relevant	 genes	 are	 active;	 both	
copies	 inherited	 form	 the	mother	 are	normally	
imprinted/switched	off,	and	the	normally	active	
one	from	the	father	is	absent.
Imprinting centre defects (ID)	
As	 chromosome	 15	 has	 an	 imprinted	 region,	
the	 IC,	 the	maternally	 inherited	 copy	behaves	
differently	 from	 the	 paternally	 inherited	 copy.	
Imprinting	 explains	 why	 the	 deletions	 that	
occur	in	PWS	always	arise	in	the	paternal	copy	
of	 chromosome	 15.	 A	mutation	 of	 the	 IC	 on	
chromosome	 15	 can	 result	 in	 PWS.	 There	 is	
no	 loss	 or	 physical	 change	 in	 the	 relevant	
genes,	rather	their	epigenetic	control	has	been	
disrupted,	 resulting	 in	no	expression	 from	 the	
copy	inherited	from	the	father.	
Table 1. Causes of PWS 
Subtype Description Results in
Deletions Type I BP1–BP3 Affects the critical PWS region. The 
chromosome is present but the PWS critical 
region is deleted or lost; there is no active 
copy of the genes, resulting in PWS
Type II BP2–BP3
mUPD Maternal uniparental 
disomy
Affects the critical PWS region. The 
chromosome is absent because of mUPD; 
there is no active copy of the genes as the 
maternally inherited copies have a normally 
silenced region, resulting in PWS
ID Imprinting centre 
defects
Affects the imprinting centre in the critical 
PWS region. The imprinting centre is 
present but is deleted or mutated; there 
is no expression or function of the centre, 
resulting in PWS
PWS critical region AS critical region
PWS critical region AS critical region
Paternal copy of chromosome 15
Maternal copy of chromosome 15
Figure 1. Paternally and maternally inherited chromosomes 15 denoting imprinted/
silenced regions (red) and expressed regions (green). AS=Angelman syndrome; 
PWS=Prader–Willi syndrome 
Figure 2. Genetic composition of chromosome 15 (note only key genes are denoted 
along the chromosome). AS=Angelman syndrome; BP1. BP2 and BP3=breakpoints; 
genes (1=four genes between BP1 and BP2; 2=a number of genes that include 
the imprinting centre; 3=a cluster of five snoRNA genes; 4=the UBE3A and 
ATP10A genes; 5=a cluster of gamma-aminobutyric acid (GABA) receptor genes); 
IC=imprinting centre; PWS=Prader–Willi syndrome
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Other causes
Translocations	have	been	 identified	as	a	 cause	
of	 PWS	 in	 a	 small	 number	 of	 cases,	 whereby	
there	 is	 an	 exchange	 of	 material	 between	 or	
within	 chromosomes,	 affecting	 chromosome	
15	 (Online	 Mendelian	 Inheritance	 in	 Man®	
(OMIM®),	2012;	PWSA(UK),	2012).	
Regions of 15q11.2–13 and associated 
genes
The	 15q11.2–13	 region	 is	 divided	 into	 four	
regions:
	A	non-imprinted	region	between	BP1	and	BP2	
containing	four	genes	—	a	deletion	involving	
this	region	has	been	linked	with	behavioural	
and	autistic	features	(Butler,	2011)
	A	 ‘PWS	 paternally-only	 expressed	 region’	
containing	 a	 number	 of	 genes,	 including	 a	
cluster	of	five	snoRNA	genes
	An	 ‘AS	 region’	 containing	 the	 maternally-
expressed	 genes	 UBE3A	 and	 ATP10A,	 with	
the	UBE3A	being	responsible	for	AS
	A	non-imprinted	region,	including	a	cluster	of	
three	GABA	receptor	genes.	
There	 are	 about	 100	 genes	 in	 the	 q11–13	
region	 between	 BP1	 and	 BP3,	 and	 about	 10	
of	 these	 genes	 are	 imprinted	 and	 paternally	
expressed.	
Butler	 (2011)	 highlights	 that	 PWS	 appears	
not	 to	 be	 caused	 by	 a	 single	 locus	 or	 gene	
mutation,	but	by	a	deficiency	of	a	combination	
of	 imprinted	 genes	 in	 the	 15q11–13	 region.	
The	snoRNAs	genes	appear	to	be	a	key	region	
expressing	 the	 phenotype	 of	 PWS,	 including	
the	 abnormal	 eating	 behaviour	 (Cassidy	 and	
Driscoll,	2009;	McAllister	et	al,	2011)	(Figure 2).	
The phenotype of PWS
There	are	recognizable	features	associated	with	
PWS,	including	neurological	and	developmental	
delay	and	behavioural	and	psychiatric	difficulties	
(Cassidy	 and	 Driscoll,	 2009;	 Butler,	 2011;	
McAllister	 et	 al,	 2011;	 McCandless	 and	 The	
Committee	on	Genetics,	 2011;	 Sinnema	et	 al,	
2011a;	OMIM®,	2012;	PWSA(UK),	2012).	Three	
key	features	of	PWS	are:
	Hypotonia
	Hyperphagia
	 Behavioural	difficulties.
These	are	 considered	 in	 the	 context	of	 central	
obesity,	which	is	a	clear	phenotypical	feature	of	
PWS.
Hypotonia
The	 ‘early	 failure	 to	 thrive’	 phase	 reflects	
the	 impact	 of	 hypotonia	 (low	 muscle	 tone),	
beginning	prenatally	and	causing	developmental	
delay	 in	 the	 prenatal	 and	 infancy	 periods.	 The	
hypotonia	results	in	diminished	swallowing	and	
sucking	 reflexes,	 leading	 to	 feeding	 difficulties	
and	poor	weight	gain.
Hyperphagia
The	 phase	 of	 ‘childhood	 obesity’	 reflects	 the	
impact	of	hyperphagia	(overeating).	The	feeding	
pattern	 of	 the	 infant	 is	 reported	 as	 changing	
around	 the	 age	 of	 18	months,	 and	 by	 about	
2	years	 the	 child	 will	 start	 gaining	 weight	 and	
will	 show	 an	 extreme	 interest	 in	 food.	 People	
with	 PWS	 appear	 to	 be	 lacking	 in	 the	 normal	
appetite	control	mechanisms	and	appear	to	have	
a	 seemingly	 insatiable	 appetite.	 However,	 the	
weight	gain	is	not	only	caused	by	overeating,	as	
people	with	PWS	have	a	lower	metabolic	rate.	
The	 hyperphagia	 is	 hypothalamic	 in	 origin,	
thought	 to	 be	 caused	 by	 a	 faulty	 mechanism	
somewhere	 within	 the	 hypothalamic	 control	
system.	This	results	in	a	lack	of	sense	of	satiety	
(fullness),	 and	 therefore	 people	 with	 PWS	
continue	to	feel	hungry	even	after	eating	more	
food	than	would	be	considered	normal;	they	may	
eventually	feel	full,	but	will	start	to	feel	hungry	
again	 much	 sooner	 than	 others.	 Therefore,	
PWS	should	be	viewed	as	not	wanting	to	stop	
eating	—	a	disorder	of	satiety	rather	than	always	
wanting	 to	 start	 eating	 because	 of	 hunger	
(McAllister	 et	 al,	 2011).	 Purtell	 and	 colleagues	
(2011)	note	that	in	healthy	subjects,	hunger	and	
satiety	operate	in	balance;	when	one	is	high,	the	
other	is	low.		
If	food	intake	is	not	controlled,	central	obesity	
(abdominal	 obesity)	 results	 from	 this	 abnormal	
eating	behaviour,	combined	with	a	low	metabolic	
rate	and	decreased	activity	level.	Theodoro	et	al	
(2006)	 looked	at	 studies	 comparing	 individuals	
with	 PWS	 and	 obese	 subjects,	 and	 reported	
differences	in	the	lean	mass	of	trunk	and	limbs;	
people	 with	 PWS	 	 demonstrated	 an	 unusual	
body	composition	and	unusual	fatness	patterns.	
People	 with	 PWS	 have	 an	 extreme	 interest	
in	 food,	 as	 shown	 by	 common	 ‘food	 seeking	
behaviours’	such	as	foraging,	stealing	of	foods,	
hording,	 eating	 of	 unappealing	 food	 items	
(frozen,	 discarded	 and	 uncooked	 foods)	 and	
eating	of	non-food	items	(pica).
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Behavioural difficulties
Behavioural	 difficulties	 are	 clearly	 associated	
with	 PWS,	 beginning	 in	 early	 childhood.	 As	
well	as	the	preoccupation	with	food	and	food-
seeking	behaviour,	other	behaviours	include:
	 Temper	outbursts
	 Skin	picking
	 Stubbornness
	Compulsive	behaviours
	Difficulties	with	change	in	routine.	
Phenotypic phases of PWS
It	 is	 clear	 from	 this	 classic	 view	 of	 PWS	 that	
the	 key	 developmental	 stages	 appear	 to	 be	
early	 infancy:	 hypotonia	 from	 18	months,	with	
a	 change	 in	 feeding	 pattern;	 and	 hyperphagia	
from	 18	months–2	years,	 with	 resultant	 central	
obesity.	
More	recently,	the	phenotype	of	PWS	has	been	
described	in	terms	of	five	phases	(Table 2),	with	
a	more	gradual	transition	between	phases	rather	
than	 a	 distinct	 switch	 (McAllister	 et	 al,	 2011;	
Miller	 et	 al,	 2011).	 A	 key	 difference	 between	
the	traditional	view	and	the	current	one	is	that	
the	development	of	hyperphagia	in	the	current	
view	is	around	the	age	of	8	years,	which	is	much	
older	 than	 the	 traditional	 18	months–2	years	
and	therefore	affects	the	care	and	management	
required	 for	 this	 phenotypical	 feature	 of	 PWS.	
Furthermore,	in	the	current	view	it	is	noted	that	
in	phase	2a	the	obesity	may	develop	before	the	
onset	of	hyperphagia	 in	phase	3	 (McAllister	et	
al,	2011;	Miller	et	al,	2011);	this	is	an	important	
issue	when	working	with	parents	 regarding	an	
effective	dietary	regimen.	
Other	 features	 have	been	described	 in	 PWS,	
including:	 hypogonadism,	 intellectual	 disability,	
a	particular	facial	appearance,	short	stature	as	a	
result	of	growth	hormone	deficiency,	decreased	
pain	 sensitivity,	 rarely	 vomiting	 and	 behaviour	
such	as	skin	picking	(Cassidy	and	Driscoll,	2009;	
Soni,	2010;	Butler,	2011;	McAllister	et	al,	2011;	
McCandless	 and	 The	 Committee	 on	 Genetics,	
2011;	 PWSA(UK),	 2012).	 Furthermore,	 the	
complications	 associated	 with	 obesity	 are	 the	
major	 causes	 of	 morbidity	 and	 mortality	 for	
people	 with	 PWS,	 including:	 cardiorespiratory	
insufficiency,	 obstructive	 sleep	 apnoea,	 type	 2	
diabetes	mellitus	and	concerns	such	as	choking	
on	gorged	food	and	rupture	 following	binging	
(Blows,	2011;	Brambilla	et	 al,	2011;	McAllister	
et	al,	2011;	PWSA(UK),	2012).	
Theoretical explanations for hyperphagia
The	liver,	vagus	nerve	and	hypothalamic	pathway	
play	a	key	role	in	food	intake	regulation;	the	liver	
relays	information	to	the	brain,	and	the	part	of	
the	 hypothalamus	 receiving	 this	 is	 dependent	
upon	 glucose	 and	 fatty	 acid	 blood	 levels	
(Zanutto	 and	 Staddon,	 2007).	 If	 these	 levels	
are	 low,	 the	 lateral	 hypothalamus	 stimulates	
hunger;	if	these	levels	are	high,	the	ventromedial	
hypothalamus	 initiates	 the	 sensation	 of	 satiety	
(Williams	 et	 al,	 2000).	 Blows	 (2011)	 discusses	
the	 role	 of	 various	 parts	 of	 the	 brain	 and	 the	
role	of	leptin	(a	hormone	released	by	adipose)	in	
food	regulation.	
The	 exact	 aetiology	 of	 the	 transition	 from	
poor	 feeding	 and	 failure	 to	 thrive	 seen	 in	 the	
early	 phases	 to	 the	 obesity	 and	 hyperphagia	
of	 the	 later	 phases	 has	 yet	 to	 be	 established,	
but	 it	 is	 thought	 that	 the	 hyperphagia	 and	
endocrine	difficulties	are	caused	by	generalized	
hypothalamic	 dysfunction	 (McAllister,	 2011;	
Miller	et	al,	2011;	PWSA(UK),	2012).	
Research	 into	 the	 role	 of	 hormones	 and	
proteins	 in	 PWS	 aims	 to	 ascertain	 the	 precise	
underlying	 dysfunction	 to	 determine	 potential	
treatments;	 however,	 no	 clear	 understanding	
exists	and	reports	are	often	contradictory	(Purtell	
et	al,	2011).	
Recent	research	topics	include:
	 Insulin	sensitivity	—	this	is	higher	in	people	with	
PWS;	however,	the	role	of	insulin	in	PWS	remains	
obscure		with	a	suggestion	of	a	differing	role	in	
Table 2. Five phases of PWS
Five phases
(with subphases in 
phases 1 and 2)
Description
0. In utero Decreased foetal movements and lower birth weight 
1. Infant Hypotonia, not obese 
1a. 0–9 months — difficulty with feeding 
1b. 9 months–2.5 years — infant grows satisfactorily 
with normal appetite 
2. Weight gain 2a. 2.1–4.5 years — weight increasing, no changes in 
appetite 
2b. 4.5–8 years — weight increases, increased interest 
in food 
3. Development of 
hyperphagia
8 years — food-seeking behaviour and lack of satiety 
4. No longer an 
insatiable appetite 
No longer has an insatiable appetite and is able to feel 
full 
Only observed in adulthood
From: Miller et al (2011)
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PWS	(Haqq	et	al,	2011),	although	no	definite	
evidence	is	available	(Purtell	et	al,	2011)	
	Ghrelin	 —	 this	 is	 an	 orexogenic	 hormone	
produced	 in	 the	 stomach	 and	 pancreas	 that	
increases	 appetite;	 higher	 levels	 have	 been	
reported	 in	 people	 with	 PWS	 (Miller	 et	 al,	
2011;	 Purtell	 et	 al,	 2011;	 PWSA(UK),	 2012)	
and	Yi	et	al	(2011)	reported	altered	levels,	but	
McAllister	and	colleagues	(2011)	suggest	that	
the	role	in	PWS	has	yet	to	be	fully	established	
	 Peptide	 YY	 (PYY)	 —	 this	 is	 a	 pancreatic	
polypeptide	 with	 anorexigenic	 actions	
(appetite	 suppressant);	 low	 levels	 of	 this	
hormone	 are	 reported	 in	 people	 with	 PWS	
(PWSA(UK),	 2012),	 although	 its	 role	 in	 PWS	
has	yet	to	be	established	(Purtell	et	al,	2011)	
	Glycogen-like	 peptide-1	 (GLP-1)	 —	 this	 has	
several	 functions,	 including	 increasing	 insulin	
secretion	and	satiety;	however,	its	role	in	PWS	
has	yet	to	be	established	(Purtell	et	al,	2011)
	 Fat	 distribution	 in	 people	 with	 PWS	 —	
differences	 in	 fat	 distribution	 can	 influence	
hormone	 levels;	 however,	 in	 PWS	 there	 is	
currently	no	clear	understanding	(Haqq	et	al,	
2011;	Purtell	et	al,	2011)		
	Genetics	—	no	direct	link	has	been	established	
to	genes	located	at	15q11.2–13;	it	is	therefore	
suggested	 that	 the	 consequence	 of	 genetics	
on	the	hypothalamic	feeding	pathway	and	the	
role	of	 the	prenatal	 environment	 remain	key	
research	areas	(McAllister	et	al,	2011).	
Care and management of PWS 
A	 key	 priority	 is	 early	 identification	 and	 a	
differential	 diagnosis,	 as	 there	 are	 several	
disorders	 that	 can	 resemble	 PWS.	 Once	 the	
diagnosis	 has	 been	 established,	 appropriate	
care	and	management	can	be	put	in	place.	This	
consists	 of	 proactive	 (anticipatory)	 and	 reactive	
care	 strategies,	 management	 and	 guidance	 in	
terms	of	responding	to	the	various	phenotypical	
features	 of	 PWS	 at	 specific	 age-dependent	
stages.	As	 people	with	 PWS	have	 a	 shorter	 life	
expectancy,	 the	 literature	 depicting	 the	 care	 of	
people	 with	 PWS	 in	 later	 adulthood	 is	 limited.	
Thus	people	reaching	this	lifetime	stage	are	often	
cared	for	in	a	more	reactive	manner	in	terms	of	
the	emergence	of	any	new	phenotypical	features.	
Proactive/anticipatory strategies 
Proactive	 strategies	 can	 be	 put	 in	 place	 as	
the	 early	 phenotypical	 features	 of	 PWS,	 such	
as	 hypotonia	 and	 hyperphagia,	 are	 well	
documented.	Proactive	strategies	include:	
	Assisted	 feeding	 to	 overcome	 feeding	
difficulties,	 such	 as	 with	 feeding	 tubes	
(nasogastric)
	 Establishing	 a	 regular	 feeding	 pattern	 to	
ensure	adequate	nutrition	as	infants	with	PWS	
rarely	wake	to	feed	or	are	undemanding.	
Proactive	strategies	for	hyperphagia	include:	
	A	dietary	regimen,	such	as	regular	meal	times	
with	a	calorie-balanced	diet	but	with	 limited	
portion	sizes
	 The	 secure	containment	of	 food,	which	may	
necessitate	 locking	 the	 refrigerator	and	 food	
cupboards	 and	 notifying	 others	 to	 do	 this,	
including	the	school	and	other	relevant	carers
	 Responding	to	the	features	as	they	arise,	such	
as	the	stealing	and	foraging	of	foods	and	pica,	
as	 the	 impact	of	hyperphagia	may	dominate	
the	lives	of	people	with	PWS	as	well	as	their	
families	and	carers
	As	a	result	of	the	erratic	nature	of	the	eating	
patterns	in	people	with	PWS,	McCandless	and	
The	Committee	on	Genetics	(2011)	note	that	
parents	should	be	informed	that	food	offered	
as	a	 reward	or	 the	withholding	of	 food	as	a	
punishment	 is	 counterproductive	 and	 should	
be	avoided.
There	 is	 no	 effective	medication	 available	 for	
hyperphagia	 and	 obesity	 (Cassidy	 and	 Driscoll,	
2009;	Butler,	2011;	McAllister	et	al,	2011;	Purtell	
et	al,	2011;	PWSA(UK),	2012).	However,	Cassidy	
and	 Driscoll	 (2009)	 and	 the	 PWSA(UK)	 (2012)	
report	 that	 dramatic	 benefits	 can	 be	 achieved	
for	 people	 with	 PWS	 by	 appropriate	 care	 and	
management,	in	terms	of	the	phenotype,	health	
and	self-image.	The	severity	of	 the	obesity	can	
be	managed	by	early	diagnosis,	diet	restrictions,	
controlling	 access	 to	 food	 and	 tailored	
exercise	 programmes	 (Sinnema	 et	 al,	 2011b).	
However,	 weight	 control	 by	 strictly	 restricting	
calorific	 intake	 may	 lead	 to	 physiological	 and	
psychological	stress	 (Dykens	et	al,	2011;	Grolla	
et	al,	2011).	Grolla	and	colleagues	(2011)	have	
reported	 successful	 weight	 loss	 and	 weight	
control	 by	 exercise	 and	 physical	 therapies	
without	strict	dietary	restrictions.	
The	 improvement	 and	 benefits	 of	 growth	
hormone	 therapy	 has	 been	 demonstrated,	
although	undesired	side	effects	and	controversies	
over	their	use	have	been	reported	(Cassidy	and	
Driscoll,	 2009;	 Butler,	 2011;	 McCandless	 and	
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The	Committee	on	Genetics,	2011).	
Advice	 and	 guidance	 is	 available	 from	
associations	 such	 as	 the	 Prader-Willi	 Syndrome	
Association	 UK	 (2012)	 and	 the	 Prader-Willi	
Syndrome	Association	USA	(2012).		
Psychological implications 
The	 features	 of	 PWS	 have	 not	 only	 practical	
implications	 but	 psychological	 ones	 as	well	 for	
the	people	with	PWS,	their	family	members	and	
carers;	 each	 phenotypical	 feature	 (symptom)	
merits	 consideration	 in	 its	 own	 right.	 PWS	 can	
affect	 self-image	 and	 self-esteem,	 and	 further	
lead	to	psychiatric	difficulties	such	as	depression.	
The	 resultant	 impaired	 cognitive	 functioning	
in	 PWS	 further	 complicates	 the	 psychological	
implications,	 as	 people	 with	 PWS	 experience	
impairment	 of	 cognitive	 processes	 that	 hinder	
their	understanding	and	managing	of	their	own	
phenotypical	features	and	associated	behaviours.
The	 hyperphagia	 and	 constant	 foraging	
for	 food	 can	 overshadow	 developmental	
behaviours;	it	is	therefore	important	to	consider	
the	 child/adolescent	 developmental	 stages	 and	
life	 experiences,	 rather	 than	 fixating	 on	 this	
feature	of	PWS.	The	phenotypic	features	of	the	
condition	 and	 the	 restrictions	 that	 these	 place	
on	the	life	experiences	of	the	person	with	PWS	
and	other	 family	members	should	therefore	be	
of	central	concern	to	all	involved	in	that	person’s	
care	and	management.	
A	multidisciplinary	team	approach	is	essential	
in	 addressing	 the	 varying	 needs	 of	 the	 person	
with	 PWS	 and	 family,	 and	 should	 include	
physical,	 speech	and	occupational	 therapists,	a	
dietician,	education,	counselling	and	psychiatric	
assessment/treatment	 (Goldstone	 et	 al,	 2008).	
Care	 strategies	 are	 required	 throughout	 the	
lifetime	of	the	person	with	PWS,	as	the	phenotypic	
features	 are	 lifelong	 and	 therefore	 necessitate	
specific	age-dependent	interventions.		 GN
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